SPIA
ADCT icon

Steward Partners Investment Advisory’s ADC Therapeutics ADCT Stock Holding History

Steward Partners Investment Advisory’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-125
Closed -$3.05K – 7066
2021
Q1 		$3.05K Buy
+125
New +$3.62K ﹤0.01% 3135

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Steward Partners Investment Advisory's ADCT Position: Q2 2021 in Review

Steward Partners Investment Advisory sold out of ADC Therapeutics (ADCT) in Q2 2021, closing a stake of 125 shares — an estimated $3.05K sold.

Steward Partners Investment Advisory first reported a position in ADCT in Q1 2021 and held it in 1 quarter. The position peaked at $3.05K in Q1 2021. 56 funds tracked by Wall St. Rank hold ADCT as of Q2 2021.

  • Steward Partners Investment Advisory reported no remaining ADC Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 125 ADC Therapeutics shares in Q2 2021, an estimated $3.05K.
  • Steward Partners Investment Advisory first reported a position in ADC Therapeutics in Q1 2021 and held it in 1 quarter.
  • Steward Partners Investment Advisory's ADC Therapeutics position peaked at $3.05K in Q1 2021.
  • 56 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.